• SIGN IN
  • GET HELP
  •  

    Webinar Details


    Event Type

    Live Online

    Date

    Monday, September 21, 2020

    Time

    10:30 AM - 12:00 PM ET

    Location

    PharmCon Webinar Studio (freeCE.com)

    Credits

    1.5 Contact Hour(s)

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $0.00

    • Overview

      Co-morbidities are common in patients with heart failure, with evidence showing over half of these patients suffer from an additional chronic disease state. One of those disease states is diabetes. The inter-relationship between heart failure and diabetes has been well-documented with estimations of 20-40% of patients with heart failure also having diabetes. Diabetes is also an independent risk factor for developing heart failure; patients with diabetes are up to two times more likely to develop heart failure than those without diabetes.  We developed this activity to address the potential gaps in pharmacist knowledge of the importance of guideline directed medical therapy and the impact on heart failure related outcomes and the expanded indications of previously approved glucose lowering therapies in patients with type 2 diabetes and established cardiovascular disease.


      Handouts

      Slide Document 20185L01_6pp.pdf
      Slide Document 20185L01_2pp.pdf





      Financial Support By

      AstraZeneca
    • Pharmacist

      Outline the guideline directed medical therapy for patients with co-morbid diabetes and cardiovascular disease
      Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with co-morbid type 2 diabetes and cardiovascular disease and in those with heart failure alone.
      Describe a patient with heart failure who would benefit from the addition of a SGLT2 inhibitor to their medication therapy.
      Identify appropriate strategies to communicate the evidence-based treatment approaches for patients with comorbid diabetes and heart failure to both patients and members of the healthcare team.

      Pharmacy Technician

      Outline the guideline directed medical therapy for patients with co-morbid diabetes and cardiovascular disease
      Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with co-morbid type 2 diabetes and cardiovascular disease and in those with heart failure alone.
      Describe a patient with heart failure who would benefit from the addition of a SGLT2 inhibitor to their medication therapy.
      Identify appropriate strategies to communicate the evidence-based treatment approaches for patients with comorbid diabetes and heart failure to both patients and members of the healthcare team.

      Nurse

      Outline the guideline directed medical therapy for patients with co-morbid diabetes and cardiovascular disease
      Compare and contrast evidence-based treatment options that optimize glycemic control and reduce cardiovascular events in patients with co-morbid type 2 diabetes and cardiovascular disease and in those with heart failure alone.
      Describe a patient with heart failure who would benefit from the addition of a SGLT2 inhibitor to their medication therapy.
      Identify appropriate strategies to communicate the evidence-based treatment approaches for patients with comorbid diabetes and heart failure to both patients and members of the healthcare team.
    • Repeat Presentation

      This presentation was last given on 10/13/2020 8:00 PM

      Future Airings

      Date Time
      Thursday, October 1, 2020 8:00 PM View
      Tuesday, October 13, 2020 8:00 PM View
      Tuesday, November 17, 2020 5:00 PM View
      Tuesday, November 24, 2020 5:00 PM View

    • Activity Type

      Knowledge

      CE Broker

      20-706371

      Universal Activity Number

      Pharmacist 0798-0000-20-185-L01-P

      Pharmacy Technician 0798-0000-20-185-L01-T

      Nurse 0798-0000-20-185-L01-N

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon, Inc. is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, attendees must answer poll questions and complete a program evaluation. Attendees may immediately print their Statement of Credit or leave them stored on the website.


    HARDWARE REQUIREMENTS
    Windows 8.1
    Windows 10
    Apple Mac OS X 10.13 or higher
    iOS 10+
    Android 4.3+


    SOFTWARE REQUIREMENTS
    Google Chrome
    Mozilla Firefox

    Log in locally; do not log in using a VPN, cloud server, remote desktop, etc.


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon. Through this notice, PharmCon. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).




    Computer sharing is NOT permitted due to accreditation guidelines on activity monitoring. Credit is earned by one user per device.